Localization of 11 beta-hydroxysteroid dehydrogenase type II in human epithelial tissues.

The enzyme 11 beta-hydroxysteroid dehydrogenase type II (11 beta HSD2) confers specificity on the renal mineralocorticoid receptor by inactivating glucocorticoids. Mutations in this gene give rise to the syndrome of apparent mineralocorticoid excess, a congenital condition characterized by sodium retention, severe hypertension, and often by growth retardation. It is not known whether 11 beta HSD2 or another enzyme confers specificity in nonrenal sodium transporting epithelia, such as those in the sweat gland, salivary gland, and gastrointestinal tract. We previously have used the HUH23 antibody to localize 11 beta HSD2 in the human kidney, vascular smooth muscle cells, and placenta. In the present study, we have examined a range of human epithelia for the presence of 11 beta HSD2. In the skin, staining was seen in eccrine sweat glands and arterioles, whereas weak HUH23 immunostaining was observed in the epidermis. Staining was absent from sebaceous glands and hair follicles. In the parotid gland, the 11 beta HSD2 enzyme was present in striated and excretory ducts, whereas in the submandibular gland, it was found in striated and interlobular ducts. Acini, adipocytes, and associated tumor tissue did not stain with the HUH23 antibody. In the gastrointestinal tract, HUH23 stained ileal enterocytes, colonic absorptive cells, and epithelial goblet cells, whereas the rectum contained areas of staining and nonstaining absorptive cells. Gastrointestinal structures, such as the lamina propria, Peyer's patch, and goblet cells within the crypts of Lieberkuhn did not stain with the antibody. This study demonstrates the presence of 11 beta HSD2 in nonrenal sodium-transporting epithelia and describes a range of tissues affected in the syndrome of apparent mineralocorticoid excess.

[1]  D. Milford,et al.  Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydrogenase type 2 gene , 1996, The Lancet.

[2]  W. B. Reeves,et al.  Immunolocalization of NAD-dependent 11 beta-hydroxysteroid dehydrogenase in human kidney and colon. , 1996, Kidney international.

[3]  T. Mune,et al.  Human hypertension caused by mutations in the kidney isozyme of 11β–hydroxysteroid dehydrogenase , 1995, Nature Genetics.

[4]  M. Fromm,et al.  Enzyme- and mineralocorticoid receptor-controlled electrogenic Na+ absorption in human rectum in vitro. , 1995, The American journal of physiology.

[5]  J. Dowling,et al.  Immunohistochemical localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. , 1995, The Journal of clinical endocrinology and metabolism.

[6]  A. Náray-Fejes-Tóth,et al.  A new isoform of 11 beta-hydroxysteroid dehydrogenase in aldosterone target cells. , 1993, The Journal of biological chemistry.

[7]  P. Fuller,et al.  Colonic sodium-potassium adenosine triphosphate subunit gene expression: ontogeny and regulation by adrenocortical steroids. , 1990, Endocrinology.

[8]  P. Fuller,et al.  Mineralocorticoid receptor gene expression in the gastrointestinal tract: distribution and ontogeny. , 1990, Journal of steroid biochemistry.

[9]  J. Whitworth,et al.  Studies on spirolactone steroid antagonists in ACTH-induced hypertension in sheep. , 1989, Journal of steroid biochemistry.

[10]  C. Edwards,et al.  Localisation of 11 beta-hydroxysteroid dehydrogenase--tissue specific protector of the mineralocorticoid receptor. , 1988, Lancet.

[11]  J. Funder,et al.  Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. , 1988, Science.

[12]  G. Litwack,et al.  Characterization of the rat colonic aldosterone receptor and its activation process. , 1986, The Journal of biological chemistry.

[13]  A. Heidland,et al.  Cation Excretion and Kallikrein Secretion by the Rat Parotid Gland in Various Hypertensive Models , 1984, Journal of cardiovascular pharmacology.

[14]  J. Funder,et al.  Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[15]  F. Anderson,et al.  Inactivation of corticosteroids in intestinal mucosa by 11 beta-hydroxysteroid: NADP oxidoreductase (EC 1.1.1.146). , 1983, The American journal of gastroenterology.

[16]  M. New,et al.  A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. , 1979, The Journal of clinical endocrinology and metabolism.